Hepatic Disease in HIV-Infected Patients
Summary
- Patients who refuse or are unable to tolerate HIV therapy or who are HIV long-term nonprogressors should be assessed for HBV disease stage; if active liver disease, patients should receive either peginterferon alfa-2a 180 µg once weekly for 48 weeks or peginterferon alfa-2b 1.5 µg/kg once weekly for 48 weeks (Management Guidelines)[DHHS OI]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content